Hyperprolactinemia after low dose of amisulpride

Neuroendocrinology Letters

Volumn 25, Issue 6, 2004, Pages 419-422

  Kopecek, Miloslav ^a,b   Bares, Martin ^a,b   Svarc, Jirí ^a   Dockery, Colleen ^a,b   Horácek, Jirí ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Amisulpride; Depression; Prolactinemia; Safety; Side effects

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DENIBAN; DIBENZEPIN; GINKGO BILOBA EXTRACT; MAPROTILINE; PINDOLOL; PROLACTIN; PROMETHAZINE; REBOXETINE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG POTENTIATION; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MALE; MASTALGIA; MONOTHERAPY; PROLACTIN BLOOD LEVEL; RANK SUM TEST; SEX RATIO;

EID: 13644254923     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Grunder G, Benkert O. Prolactin secretion is not a core dimension of "atypicality". Psychopharmacology (Berl) 2002; 162 93.
2. Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk I, Ahtoy P, et al. Safety and pharmacokinetic of single oral dose of amisulpride in healthy volunteers. Eur J Clin Pharmacol 1998; 54 405-409.
3. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520.
4. Kapur S, Langlois X, Vinken P, Megens AAHP, De Coster R, Andrews JS The differential effects of atypical Antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Experimetal Therapeutics 2002; 302:1129-1134.
5. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159:180-190.
6. Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1101-1111.
7. Mota Neto JIS, Lima MS, Soares BGO. Amisulpride for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2 2002. Oxford: Update Software.
8. Noble S, Benfield P. Amisulpride; a review of its clinical potential in dysthymia. CNS Drugs 1999; 12:471-483.
9. Petty RG. Prolactin and antipsychotic medications: Mechanism of action. Schizophrenia-Research. 1999; 35/SUPPL. (S67-S73).
10. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97.
11. Wetzel H, Wiesner J, Hiemke C, Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994; 28: 461-473.
12. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'HC, Maziere B, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503-508.